Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced positive data with Pegylated Interferon Lambda (Lambda) in the Phase 2 LIMT HDV ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) InfectionOctober 17, 2018 4:05 PM Eiger BioPharma (EIGR) PT Raised to $28 at Ladenburg ThalmannOctober 17, 2018 10:09 AM After-Hours Movers 10/16: (NFLX) (UAL) (LRCX) Higher; (EIGR) (IBM) (UFPI) Lower (more...)October 16, 2018 5:08 PM Eiger BioPharmaceuticals (EIGR) to Resume Trading at 4:35 pm ETOctober 16, 2018 4:28 PM Eiger BioPharmaceuticals (EIGR) Halted, News PendingOctober 16, 2018 4:03 PM